STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

Title and abstract (a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found Introduction Background/rationale 2 Explain the scientific background and rationale for the investigation being reported Objectives 3 State specific objectives, including any prespecified hypotheses 2-3 Methods Study design 4 Present key elements of study design early in the paper 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Data sources/ 8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Bias 9 Describe any efforts to address potential sources of bias 4-5 Study size 10 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical methods 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical methods 11 (a) Describe any methods used to examine subgroups and interactions (b) and participates, explain how missing data were addressed (d) if applicable, explain how missing data were addressed (d) if applicable, explain how loss to follow-up, was addressed (d) if applicable, completing follow-up, and analysed (d) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Give c		Item No	Recommendation	Page No
Introduction Service Explain the scientific background and rationale for the investigation being reported 2	Title and abstract		(a) Indicate the study's design with a commonly used term in the title or the	Title page
Date sources 8* For each variable of interest, give sources of data and details of methods of assessment (measurement) Describe and variable of interest, give sources of bias 4.5			(b) Provide in the abstract an informative and balanced summary of what was	
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 2			done and what was found	
Disectives State specific objectives, including any prespecified hypotheses 2-3	Introduction			
Securities Sec	Background/rationale	2		2
Study design	Objectives	3	State specific objectives, including any prespecified hypotheses	2-3
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Data sources/ 8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Bias 9 Describe any efforts to address potential sources of bias 4-5 Study size 10 Explain how the study size was arrived at 3 Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3	Methods			
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Data sources/ 8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Bias 9 Describe any efforts to address potential sources of bias 4-6 Study size 10 Explain how the study size was arrived at 2 (a) Describe any last stistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (d) G) Describe any sensitivity analyses Results 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time	Study design	4	Present key elements of study design early in the paper	3
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and unexposed Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Data sources/ measurement 8* For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Bias 9 Describe any efforts to address potential sources of bias 4-6 Study size 10 Explain how the study size was arrived at 2 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how participants of eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure Coutcome data 15* Report numbers of outcome events or summary measures over time Figure Figure Figure Figure Figure Figure Figure	Setting	5		3-5
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Data sources/ measurement 8* For each variable of interest, give sources of data and details of methods of there is more than one group Bias 9 Describe any efforts to address potential sources of bias 4-6 Study size 10 Explain how the study size was arrived at Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (d) Give reasons for non-participation at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time Figure	Participants	6		
effect modifiers. Give diagnostic criteria, if applicable Data sources/ measurement Bias 9 Describe any efforts to address potential sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Bias 9 Describe any efforts to address potential sources of bias 4-6 Study size 10 Explain how the study size was arrived at 20 Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (g) Describe any sensitivity analyses Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time Figure Figure				
Bias 9 Describe any efforts to address potential sources of bias 4-6 Study size 10 Explain how the study size was arrived at 3 Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses N/A Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Figure (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure Outcome data 15* Report numbers of outcome events or summary measures over time Figure	Variables	7	•	4-5
Bias 9 Describe any efforts to address potential sources of bias 4-6		8*	assessment (measurement). Describe comparability of assessment methods if	4-5
Study size 10 Explain how the study size was arrived at Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) 7 Table 1-2 1-2 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time Figure Figure 2-3 Outcome data	D'			1-6
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Table 1-2 Table 1-2 Coutcome data 15* Report numbers of outcome events or summary measures over time Figure 2-3				
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time Figure Figure			Explain how quantitative variables were handled in the analyses. If applicable,	
(b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses N/A Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time N/A N/A N/A N/A N/A N/A 13, 7 A Table 1-2	Statistical methods	12	(a) Describe all statistical methods, including those used to control for	6
(c) Explain flow missing data were dadressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses N/A Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time			(b) Describe any methods used to examine subgroups and interactions	
Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time				
Results Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Pigure 1 Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time				
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Pescriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time 3, 7 N/A Figure Figure 1 Table 1-2 Figure 2-3			(<u>e</u>) Describe any sensitivity analyses	N/A
potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time	Results			2.5
(b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Pigure 1 Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time	Participants	13*	potentially eligible, examined for eligibility, confirmed eligible, included in the	3, 7
(c) Consider use of a flow diagram Tigure 1 Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time				N/A
and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Table 1-2 Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time Figure 5-3				Figure 1
(b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) Outcome data 15* Report numbers of outcome events or summary measures over time Table 1-2 Figure 2-3 Figure 5-3	Descriptive data	14*		
(c) Summarise follow-up time (eg, average and total amount) Figure 2-3 Outcome data 15* Report numbers of outcome events or summary measures over time Figure 2-3			(b) Indicate number of participants with missing data for each variable of	
Outcome data 15* Report numbers of outcome events or summary measures over time Figure				Figure 2-3
	Outcome data	15*	Report numbers of outcome events or summary measures over time	Figure

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for	Table 3
		and why they were included	
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a	N/A
		meaningful time period	
Other analyses 17	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity	
		analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	8-10
Limitations 19	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	10
		Discuss both direction and magnitude of any potential bias	
Interpretation 20		Give a cautious overall interpretation of results considering objectives, limitations,	
		multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	8-10
Other informati	on		
Funding 2	22	Give the source of funding and the role of the funders for the present study and, if	6-7
		applicable, for the original study on which the present article is based	

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobestatement.org.